China Pharma Holdings (CPHI) AI Stock Analysis

• Market Cap: $7.24M
• Dividend Yield: N/A
• Average Volume (3M): 106.24K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.62
• Revenue Growth: -33.10%
• EPS Growth: 71.37%
• Country: US
• Employees: 224
• Sector: Healthcare
• Sector Strength: 42
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.07
• Shares Outstanding: 3,262,002
• 10 Day Avg. Volume: 40,729
• 30 Day Avg. Volume: 106,243
• PEG Ratio: <0.01
• Price to Book (P/B): <0.01
• Price to Sales (P/S): 0.00
• P/FCF Ratio: >-0.01
• Enterprise Value/Market Cap: 138.12K
• Enterprise Value/Revenue: 0.88
• Enterprise Value/Gross Profit: -7.35
• Enterprise Value/Ebitda: -1.32
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 37 Underperform
• Price Target: $2.00 ▼( -9.50% Downside)

China Pharma Holdings' overall stock score is significantly impacted by its weak financial performance, characterized by persistent losses and high leverage. While technical indicators show some upward momentum, the fundamental financial challenges pose significant risks. The negative P/E ratio and absence of dividend yield further weigh down the valuation, resulting in a low overall score.

China Pharma Holdings Business Overview & Revenue Model

Company Description

China Pharma Holdings, Inc. (CPHI) is a pharmaceutical company engaged in the development, manufacture, and marketing of a wide variety of pharmaceutical products. The company's primary focus is on the therapeutic areas of cardiovascular diseases, central nervous system disorders, infectious diseases, and other critical medical needs. With a strong emphasis on quality and innovation, China Pharma Holdings aims to meet the growing demand for effective and affordable healthcare solutions in China and other emerging markets.

How the Company Makes Money

China Pharma Holdings generates revenue primarily through the production and sale of pharmaceutical products. The company's revenue model is based on the commercialization of its diverse portfolio of drugs, which includes both prescription and over-the-counter medications. Key revenue streams include sales to hospitals, pharmacies, and other healthcare institutions. Additionally, China Pharma Holdings may engage in strategic partnerships with other pharmaceutical companies to expand its product offerings and market reach, thereby enhancing its revenue potential. The company's earnings are influenced by factors such as product pricing, market demand, regulatory approvals, and its ability to innovate and introduce new products to the market.

China Pharma Holdings Financial Statement Overview

Summary

China Pharma Holdings faces substantial financial challenges across income, balance sheet, and cash flow statements. Persistent losses, high leverage, and negative cash flows indicate operational and financial instability. Strategic improvements are necessary to enhance profitability, reduce debt reliance, and stabilize cash flows.

Income Statement

The income statement exhibits significant challenges, with negative gross profit and net income margins over the past years, indicating ongoing losses. Revenue growth is erratic, and both EBIT and EBITDA margins remain negative, reflecting operational inefficiencies and cost management issues.

Balance Sheet

The balance sheet reveals a high debt-to-equity ratio, indicating potential leverage risks. Return on equity is negative due to persistent losses. However, the equity ratio is moderately healthy, suggesting some asset stability despite financial distress.

Cash Flow

Cash flow analysis highlights a negative free cash flow and operating cash flow, indicating cash constraints. The ratios of operating and free cash flow to net income are unfavorable, emphasizing cash management difficulties and potential liquidity issues.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
1.14T	4.53M	7.01M	8.10M	9.64M	10.87M
	Gross Profit
-136.06B	-1.99M	-281.08K	-493.92K	349.27K	1.95M
	EBIT
-758.62B	-4.59M	-2.75M	-3.55M	-3.12M	-2.46M
	EBITDA
-758.62B	-1.96M	8.44K	-837.69K	230.34K	106.85K
	Net Income Common Stockholders
-785.58B	-4.74M	-3.08M	-10.22M	-3.94M	-3.16M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
412.69B	626.88B	1.42M	2.03M	4.86M	957.65K
	Total Assets
14.22T	15.07M	16.47M	17.78M	22.65M	21.12M
	Total Debt
1.41T	3.59M	4.63M	8.76M	12.49M	7.43M
	Net Debt
1.00T	2.96M	3.21M	6.73M	7.63M	6.47M
	Total Liabilities
7.25T	7.14M	9.01M	13.49M	16.63M	13.11M
	Stockholders Equity
6.97T	7.93M	7.45M	4.29M	6.02M	8.00M
Cash Flow		Free Cash Flow
-116.15B	-758.08K	-711.20K	-811.51K	-687.89K	-909.57K
	Operating Cash Flow
-57.82B	-466.36K	-699.69K	-409.55K	-249.84K	-42.26K
	Investing Cash Flow
-80.97B	-291.72K	-11.52K	-401.96K	-438.06K	-867.31K
	Financing Cash Flow
-70.03B	27.35K	73.14K	-1.77M	4.60M	624.18K

China Pharma Holdings Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.21
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CPHI, the sentiment is Positive. The current price of 2.21 is above the 20-day moving average (MA) of 2.10, above the 50-day MA of 2.09, and above the 200-day MA of 2.13, indicating a bullish trend. The MACD of 0.09 indicates Negative momentum. The RSI at 55.17 is Neutral, neither overbought nor oversold. The STOCH value of 44.98 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CPHI.

China Pharma Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	53 Neutral	$5.14B	3.03	-43.89%	2.83%	16.75%	-0.06%
XBIO	43 Neutral	$4.63M	―	-53.16%	―	-1.56%	5.01%
SBFM	40 Underperform	$6.56M	―	-21.17%	―	35.51%	95.44%
CPHI	37 Underperform	$7.24M	―	-59.14%	―	-33.10%	71.37%

China Pharma Holdings Corporate Events

China Pharma Holdings Announces Reverse Stock Split

On April 4, 2025, China Pharma Holdings announced a 1-for-10 reverse stock split set to take effect on April 15, 2025. This move, authorized by the Board and stockholders, will consolidate every 10 shares into one, affecting all shareholders uniformly without altering their percentage interest in the company.